Bristol Myers Squibb Expands AI Drug Discovery With NVIDIA Vera Rubin SuperPOD

Bristol Myers Squibb (BMS) is expanding its artificial intelligence (AI) infrastructure with a new NVIDIA DGX SuperPOD built on the company's Vera Rubin architecture, becoming the first life sciences company to deploy the latest-generation system for drug discovery and development.

The pharmaceutical company said the new deployment will support AI across its research organization, allowing scientists to train larger foundation models, run large-scale biological predictions, and use agentic AI workflows throughout the drug discovery pipeline. According to NVIDIA, the system consists of eight DGX Vera Rubin NVL72 systems and delivers up to 10x more performance per megawatt than the infrastructure it replaces.

The new AI cluster will operate alongside BMS' existing DGX SuperPOD, creating a unified computing environment accessible across the company's global research organization. The platform will also incorporate NVIDIA BioNeMo Agent Toolkit and NVIDIA Mission Control to support biological AI models and AI infrastructure management.

The investment reflects a broader shift toward dedicated AI infrastructure across enterprise research organizations, where compute capacity is becoming as important as proprietary data and AI models.